Adenovirus Clinical Trial
Official title:
Pilot Study of Haploidentical or Matched Donor Virus-Specific T-cells (Cytomegalovirus (CMV) or Adenovirus (AdV)) to Treat CMV or AdV Reactivation or Disease in Patients After Solid Organ or Hematopoietic Stem Cell Transplantation (HCT)
This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus [CMV] specific cytotoxic T-lymphocytes [CTLs]) or allogeneic adenovirus-specific cytotoxic T lymphocytes (donor adenovirus-specific [AdV] specific CTLs) work in treating CMV or AdV reactivation or infection in participants who have undergone stem cell transplant or solid organ transplant. White blood cells from donors may be able to kill cancer cells in patients with cytomegalovirus or adenovirus that has come back after a stem cell or solid organ transplant.
PRIMARY OBJECTIVE I. Assess the safety and feasibility of administering virus specific-CTLs from haploidentical donors in transplant patients both solid organ transplantation (SOT) and hematopoietic cell transplantation (HCT) with CMV/AdV infection despite standard therapy. OUTLINE:Patients are assigned to 1 of 2 Cohorts. COHORT A: Patients receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes intravenously (IV). Patients undergo blood, urine, saliva, cerebrospinal fluid (CSF), and bronchoalveolar fluid sample collection on the trial. COHORT B: Patients receive allogeneic adenovirus-specific cytotoxic T Lymphocytes IV. Patients undergo blood, urine, saliva, CSF, and bronchoalveolar fluid sample collection on the trial. After completion of study treatment, participants are followed up at 1 year. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
Recruiting |
NCT03266627 -
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
|
Phase 2 | |
Not yet recruiting |
NCT03325517 -
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics
|
N/A | |
Not yet recruiting |
NCT06392451 -
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
|
N/A | |
Recruiting |
NCT05183490 -
R-MVST Cells for Treatment of Viral Infections
|
Phase 1 | |
Completed |
NCT04056546 -
Interest of Rapid Typing in Adenovirus Infections.
|
||
Withdrawn |
NCT00448994 -
Adenovirus and Fungal Load in Pediatric Stem Cell Transplant Patients
|
N/A | |
Recruiting |
NCT06299813 -
Effectiveness of a Single Dose of Betamethasone in Children With Symptomatic Adenovirus Infection
|
Phase 3 | |
Enrolling by invitation |
NCT06027879 -
Anti-viral T-cell Therapy by Gamma Capture
|
Phase 1/Phase 2 | |
Recruiting |
NCT02779439 -
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
|
Phase 1 | |
Terminated |
NCT02420080 -
A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304
|
N/A | |
Active, not recruiting |
NCT01945814 -
Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
|
Phase 1 | |
Completed |
NCT01535885 -
Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV
|
Phase 1 | |
Terminated |
NCT03339401 -
The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation
|
Phase 2 | |
Withdrawn |
NCT01584037 -
Adenovirus Vaccine Pregnancy Registry
|
N/A | |
Withdrawn |
NCT03532035 -
Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia
|
Phase 2 | |
Recruiting |
NCT02008812 -
Ad Sensor-based Real-time Diagnosis of Adenovirus
|
N/A | |
Active, not recruiting |
NCT04364178 -
Viral Specific T-Lymphocytes to Treat Adenovirus or CMV
|
Phase 1/Phase 2 | |
Recruiting |
NCT05664126 -
Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation
|
Phase 2 |